"""
Question: 1101 

Evidence: We studied a Nigerian cohort of recipients prior to and during receipt of second-line PI-based therapy, who were integrase inhibitor-naive. Overall, 115 participants had a total of 163 plasma samples that yielded HIV pol sequences.

Rationale: The paper describes original data collection and analysis from a defined Nigerian cohort, including sequencing results and prevalence estimates, indicating that it reports previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Overall, 115 participants had a total of 163 plasma samples that yielded HIV pol sequences. Whole-genome deep sequencing was performed using the Illumina Miseq platform.

Rationale: The paper explicitly states that HIV pol sequences were obtained and describes the sequencing platform used, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Whole-genome deep sequencing was performed using the Illumina Miseq platform. In vitro studies are needed to determine whether L74I facilitates high-level INSTI resistance in non-B subtypes.

Rationale: The methods describe sequencing of clinical samples with no in vitro passage methods, and the discussion notes that in vitro studies are still needed, indicating that no in vitro passage experiments were performed.

Answer: No
"""

"""
Question: 1104 

Evidence: Drug resistance was interpreted using the Stanford Resistance Database and the IAS-USA 2019 mutation lists. In vitro studies are needed to determine whether L74I facilitates high-level INSTI resistance in non-B subtypes.

Rationale: The study relied on genotypic interpretation tools and explicitly calls for future in vitro work, indicating no in vitro antiretroviral susceptibility testing was performed.

Answer: No
"""

"""
Question: 2101 

Evidence: Whole-genome deep sequencing was performed using the Illumina Miseq platform. The presence and frequency of IAS-USA resistance-associated mutations in integrase, in addition to L74I, was assessed.

Rationale: Although sequencing was performed and mutations were analyzed, the paper does not provide any GenBank accession numbers in the provided text.

Answer: No
"""

"""
Question: 2102 

Evidence: Whole-genome deep sequencing was performed using the Illumina Miseq platform. Tables S1 and S2 are available as Supplementary data at JAC Online.

Rationale: The text includes no accession numbers for deposited sequences, either for clinical or laboratory isolates, indicating that such numbers were not reported.

Answer: No
"""

"""
Question: 2103 

Evidence: Whole-genome deep sequencing was performed using the Illumina Miseq platform. The presence and frequency of IAS-USA resistance-associated mutations in integrase, in addition to L74I, was assessed.

Rationale: No GenBank accession numbers appear anywhere in the provided text, so specific accession numbers cannot be listed.

Answer: NA
"""

"""
Question: 2202 

Evidence: Table 2. Participants with L74I and longitudinal sampling. pol drug resistance mutations (consensus sequence) RT: M184V, K103N, Y318F.

Rationale: Table 2 presents per-participant lists of drug resistance mutations at the consensus level, demonstrating that the paper reports mutation lists for individual sequences.

Answer: Yes
"""

"""
Question: 2301 

Evidence: HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy and resistance data for non-B subtypes are limited. Of 115 individuals, 59.1% harboured CRF02_AG HIV-1 and 40.9% harboured subtype G HIV-1.

Rationale: The study consistently refers to HIV-1 and its subtypes, indicating that the species studied is HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Of 115 individuals, 59.1% harboured CRF02_AG HIV-1 and 40.9% harboured subtype G HIV-1. L74I was more common among those with subtype G infection (55.3%, 26/47) than those with CRF02_AG infection (29.4%, 20/68).

Rationale: The results specify the subtypes of the sequenced viruses as CRF02_AG and subtype G.

Answer: CRF02_AG and G
"""

"""
Question: 2303 

Evidence: Whole-genome deep sequencing was performed using the Illumina Miseq platform. The median sequencing coverage of all samples at the whole-genome level was 583 reads per base (IQR = 136–1313), 595 (IQR = 125–1324) for the pol gene and 735 (IQR = 162–1593) for the integrase L74 codon.

Rationale: Although whole-genome sequencing was performed, the analysis emphasizes the pol gene, particularly integrase, and reports RT and protease mutations in Table 2.

Answer: Whole genome (with reported analyses of pol including integrase, reverse transcriptase, and protease)
"""

"""
Question: 2304 

Evidence: Overall, 115 participants had a total of 163 plasma samples that yielded HIV pol sequences. The median sequencing coverage ... was ... 595 (IQR = 125–1324) for the pol gene and 735 (IQR = 162–1593) for the integrase L74 codon.

Rationale: The paper explicitly states that HIV pol sequences were obtained and analyzed.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Study participants were selected from an HIV-positive second-line treatment cohort at the University of Abuja Teaching Hospital (UATH) in Abuja, Nigeria. We studied a Nigerian cohort of people living with HIV.

Rationale: The sequences were from individuals in Nigeria, specifically Abuja.

Answer: Nigeria (Abuja)
"""

"""
Question: 2402 

Evidence: The Institute of Human Virology Nigeria (IHVN) database was used to identify people living with HIV ... who had attended UATH and received a first-line ART regimen ... followed by a second-line ART regimen. Study participants were selected from an HIV-positive second-line treatment cohort at the University of Abuja Teaching Hospital (UATH) in Abuja, Nigeria.

Rationale: The paper describes the setting and cohort but does not provide specific years for sample collection.

Answer: NA
"""

"""
Question: 2502 

Evidence: Illumina next-generation sequencing with target enrichment was used on stored plasma samples. Whole-genome deep sequencing was performed using the Illumina Miseq platform.

Rationale: Sequencing was performed using Illumina NGS technology, not Sanger sequencing.

Answer: No
"""

"""
Question: 2503 

Evidence: Illumina next-generation sequencing with target enrichment was used on stored plasma samples. Whole-genome deep sequencing was performed using the Illumina Miseq platform.

Rationale: The paper explicitly states that next-generation sequencing (NGS) was used.

Answer: Yes
"""

"""
Question: 2504 

Evidence: Sample libraries were prepared as per the SureSelect XT automated target enrichment protocol (Agilent Technologies, Santa Clara, CA, USA) with in-house HIV baits. Whole-genome deep sequencing was performed using the Illumina Miseq platform.

Rationale: The methods describe library preparation for NGS without any mention of cloning of samples prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: Mutations were included if they were present at over 2% frequency within the read mixture at that position and present on at least two reads. Whole-genome deep sequencing was performed using the Illumina Miseq platform.

Rationale: The detection of low-frequency variants in read mixtures indicates bulk NGS rather than single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: Sample libraries were prepared as per the SureSelect XT automated target enrichment protocol (Agilent) with in-house HIV baits. Whole-genome deep sequencing was performed using the Illumina Miseq platform.

Rationale: There is no description of molecular cloning; the workflow used targeted enrichment and NGS.

Answer: No
"""

"""
Question: 2601 

Evidence: Illumina next-generation sequencing with target enrichment was used on stored plasma samples. Overall, 115 participants had a total of 163 plasma samples that yielded HIV pol sequences.

Rationale: Sequencing was explicitly performed on plasma samples.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Illumina next-generation sequencing with target enrichment was used on stored plasma samples. The first strand of cDNA was synthesized using SuperScript IV reverse transcriptase.

Rationale: Only plasma-derived RNA was sequenced; PBMC-derived DNA/RNA sequencing was not reported.

Answer: No
"""

"""
Question: 2603 

Evidence: Overall, 115 participants had a total of 163 plasma samples that yielded HIV pol sequences. 

Rationale: The paper directly states the number of plasma samples that produced sequences.

Answer: 163
"""

"""
Question: 2604 

Evidence: Illumina next-generation sequencing with target enrichment was used on stored plasma samples. Overall, 115 participants had a total of 163 plasma samples that yielded HIV pol sequences.

Rationale: There is no mention of PBMC virus sequencing; all reported sequences were from plasma, so the number of PBMC-sequenced samples is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: Participants were included in the study if they: (i) had experienced first-line VF, defined as HIV RNA >1000 copies/mL at least 6 months after first-line ART initiation. Table 2 lists viral loads for individual samples.

Rationale: Virological failure with detectable RNA indicates active replication at the time of sampling.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Illumina next-generation sequencing with target enrichment was used on stored plasma samples. The first strand of cDNA was synthesized using SuperScript IV reverse transcriptase.

Rationale: Sequencing was performed on plasma RNA and not on proviral DNA from PBMCs, so sequences were not obtained from the proviral reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: The IHVN database was used to identify people living with HIV (PLWH) aged >15 years who had attended UATH. 

Rationale: The inclusion criterion of age >15 years excludes infants and children.

Answer: No
"""

"""
Question: 2702 

Evidence: Study participants were selected from an HIV-positive second-line treatment cohort at the University of Abuja Teaching Hospital (UATH) in Abuja, Nigeria. 

Rationale: The cohort was a clinical treatment cohort, not a clinical trial; there is no indication that participants were enrolled in a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: Study participants were selected from an HIV-positive second-line treatment cohort at the University of Abuja Teaching Hospital (UATH) in Abuja, Nigeria. 

Rationale: Because participants were from a treatment cohort, not a clinical trial, it follows that not all participants were in a trial.

Answer: No
"""

"""
Question: 3101 

Evidence: Overall, 115 participants had a total of 163 plasma samples that yielded HIV pol sequences. 

Rationale: The paper provides the exact number of individuals whose samples were sequenced.

Answer: 115
"""

"""
Question: 3102 

Evidence: Overall, 115 participants had a total of 163 plasma samples that yielded HIV pol sequences. 

Rationale: The statement implies all 115 participants contributed sequences.

Answer: Yes
"""

"""
Question: 4101 

Evidence: Two participants had a sample obtained prior to receiving any ART. 

Rationale: This indicates that sequences from ART-naive individuals are included.

Answer: Yes
"""

"""
Question: 4102 

Evidence: 72 participants had samples from first-line ART only ... 14 participants had samples from second-line ART only ... and 27 participants had samples obtained during first-line and second-line ART. 

Rationale: These categories show that many participants had received antiretroviral drugs before their samples were obtained.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Two participants had a sample obtained prior to receiving any ART. 72 participants had samples from first-line ART only ... 14 from second-line only ... and 27 from both first-line and second-line ART.

Rationale: The study includes both ART-naive and ART-experienced samples.

Answer: Yes
"""

"""
Question: 4104 

Evidence: Two participants had a sample obtained prior to receiving any ART. 

Rationale: The number of ART-naive samples explicitly reported is two.

Answer: 2
"""

"""
Question: 4105 

Evidence: The IHVN database was used to identify PLWH ... who had received a first-line ART regimen of two NRTIs and one NNRTI, followed by a second-line ART regimen of two NRTIs and one PI (lopinavir or atazanavir). 

Rationale: The paper describes regimen classes but does not provide detailed, complete ART histories for each individual, so complete ART history information is not provided for all.

Answer: No
"""

"""
Question: 4201 

Evidence: A limitation of this study was that our patient group were mainly ART-experienced and as such there may be a different prevalence of L74I in treatment-naive individuals. 

Rationale: Transmitted resistance is assessed in ART-naive populations; the study mainly involved ART-experienced individuals and does not present prevalence data on transmitted resistance.

Answer: No
"""

"""
Question: 4202 

Evidence: Second-generation integrase inhibitors such as dolutegravir are now recommended for first-line HIV treatment regimens, following an increase in pre-treatment drug resistance to NNRTI-based regimens globally, including Nigeria. 

Rationale: Although the introduction mentions global pretreatment resistance, the study does not report pretreatment resistance prevalence data from its cohort.

Answer: No
"""

"""
Question: 4301 

Evidence: ... received a first-line ART regimen of two NRTIs and one NNRTI, followed by a second-line ART regimen of two NRTIs and one PI (lopinavir or atazanavir). 

Rationale: The drug classes received were NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, and PIs
"""

"""
Question: 4302 

Evidence: We studied a Nigerian cohort of recipients prior to and during receipt of second-line PI-based therapy, who were integrase inhibitor-naive. 

Rationale: Participants were INSTI-naive, so none received integrase inhibitors.

Answer: No
"""

"""
Question: 4303 

Evidence: ... followed by a second-line ART regimen of two NRTIs and one PI (lopinavir or atazanavir). 

Rationale: The second-line regimens included protease inhibitors, confirming that PI use was reported.

Answer: Yes
"""

"""
Question: 4304 

Evidence: ... followed by a second-line ART regimen of two NRTIs and one PI (lopinavir or atazanavir). 

Rationale: Because second-line PIs varied (lopinavir or atazanavir), not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: We studied a Nigerian cohort ... who were integrase inhibitor-naive. 

Rationale: The cohort had not received integrase inhibitors.

Answer: Yes
"""

"""
Question: 4403 

Evidence: The IHVN database was used to identify PLWH ... who had received a first-line ART regimen ... followed by a second-line ART regimen. Overall, 115 participants had a total of 163 plasma samples that yielded HIV pol sequences.

Rationale: Selection criteria indicate all included individuals had both first- and second-line ART, meaning more than one regimen.

Answer: 115
"""

"""
Question: 4404 

Evidence: ... received a first-line ART regimen of two NRTIs and one NNRTI, followed by a second-line ART regimen of two NRTIs and one PI (lopinavir or atazanavir). 

Rationale: Only first- and second-line regimens are described; there is no mention of third or additional regimens.

Answer: 0
"""

"""
Question: 4405 

Evidence: ... received a first-line ART regimen ... followed by a second-line ART regimen of two NRTIs and one PI. 

Rationale: The inclusion criteria indicate all individuals had two regimens, implying the same number of regimens across the cohort.

Answer: Yes
"""

"""
Question: 4406 

Evidence: ... received a first-line ART regimen of two NRTIs and one NNRTI, followed by a second-line ART regimen of two NRTIs and one PI. 

Rationale: Because participants had at least two regimens, not all received only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: We studied a Nigerian cohort ... who were integrase inhibitor-naive. 

Rationale: Dolutegravir is an integrase inhibitor; if all were INSTI-naive, none received dolutegravir.

Answer: 0
"""

"""
Question: 4502 

Evidence: ... followed by a second-line ART regimen of two NRTIs and one PI (lopinavir or atazanavir). 

Rationale: The PIs used were lopinavir or atazanavir; darunavir is not mentioned.

Answer: 0
"""

"""
Question: 5101 

Evidence: Four participants had major IAS-USA integrase resistance-associated mutations detected at low levels (2%–5% frequency). Another six participants had minor IAS-USA integrase resistance-associated mutations.

Rationale: The paper provides counts for integrase mutations but does not provide a comprehensive count of all drug resistance mutations across all genes for all individuals, so the total number with any DRM cannot be determined from the text.

Answer: NA
"""

"""
Question: 5102 

Evidence: Four participants had major IAS-USA integrase resistance-associated mutations detected at low levels (2%–5% frequency). Another six participants had minor IAS-USA integrase resistance-associated mutations.

Rationale: Summing major and minor INSTI-associated mutations yields 10 participants with INSTI-resistance-associated mutations.

Answer: 10
"""

"""
Question: 5103 

Evidence: Table 2 lists individual RT mutations such as K65R for some participants, but no cohort-wide counts are provided. The paper does not report the number of individuals with TDF-resistance mutations.

Rationale: Without a summarized count of TDF-resistance mutations (e.g., K65R) across the cohort, this cannot be determined from the text.

Answer: NA
"""

"""
Question: 5104 

Evidence: Two had Q148K minority variants and two had R263K (one of whom also had L74I). Another six participants had minor IAS-USA integrase resistance-associated mutations. Four had T97A, another participant had an E138K minority variant and another had a G140A minority variant.

Rationale: These sentences list the specific INSTI-resistance-associated mutations detected in participants.

Answer: Q148K, R263K, T97A, E138K, G140A
"""

"""
Question: 6101 

Evidence: Drug resistance was interpreted using the Stanford Resistance Database and the IAS-USA 2019 mutation lists. In vitro studies are needed to determine whether L74I facilitates high-level INSTI resistance in non-B subtypes.

Rationale: Only genotypic interpretation is described and the paper calls for future in vitro studies; no phenotypic susceptibility method was used.

Answer: NA
"""

"""
Question: 6102 

Evidence: Drug resistance was interpreted using the Stanford Resistance Database and the IAS-USA 2019 mutation lists. 

Rationale: The study did not perform phenotypic testing and does not report IC values such as IC50 or IC90.

Answer: No
"""

"""
Question: 6103 

Evidence: Drug resistance was interpreted using the Stanford Resistance Database and the IAS-USA 2019 mutation lists. 

Rationale: The paper does not present phenotypic IC50 fold-change measurements.

Answer: No
"""

"""
Question: 6104 

Evidence: Drug resistance was interpreted using the Stanford Resistance Database and the IAS-USA 2019 mutation lists. 

Rationale: No phenotypic susceptibility assay was used or described.

Answer: NA
"""

"""
Question: 6105 

Evidence: In vitro studies are needed to determine whether L74I facilitates high-level INSTI resistance in non-B subtypes. 

Rationale: The paper does not report replication capacity data.

Answer: No
"""

"""
Question: 6106 

Evidence: Drug resistance was interpreted using the Stanford Resistance Database and the IAS-USA 2019 mutation lists. 

Rationale: No phenotypic susceptibility testing was conducted; therefore, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: We studied a Nigerian cohort of recipients prior to and during receipt of second-line PI-based therapy, who were integrase inhibitor-naive. Illumina next-generation sequencing with target enrichment was used on stored plasma samples.

Rationale: The study analyzes clinical samples and does not describe site-directed mutagenesis or engineered isolates.

Answer: No
"""

"""
Question: 7102 

Evidence: Whole-genome deep sequencing was performed using the Illumina Miseq platform. In vitro studies are needed to determine whether L74I facilitates high-level INSTI resistance in non-B subtypes.

Rationale: There is no description of in vitro passage experiments; the paper calls for such studies in the future.

Answer: No
"""